Advice
following an abbreviated submission
mifepristone tablet and misoprostol vaginal tablets combipack (Medabon®) is accepted for use within NHS Scotland.
Indication under review: for medical termination of developing intra-uterine pregnancy of up to 63 days of amenorrhoea.
For patients in whom mifepristone and misoprostol is an appropriate choice of therapy, Medabon® provides the two components in a single pack at a lower cost than the individual components.
Download detailed advice78KB (PDF)
Medicine details
- Medicine name:
- mifepristone (Medabon)
- SMC ID:
- 913/13
- Indication:
- For medical termination of developing intra-uterine pregnancy of up to 63 days of amenorrhoea.
- Pharmaceutical company
- Sun Pharmaceuticals UK Ltd
- BNF chapter
- Obstetrics, gynaecology, and urinary-tract disorders
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 November 2014